简介内容:MK-912 is a potent novel selective alpha2-adrenergic receptor antagonist with oral activity to study the effect of short-term selective alpha2-blockers on fasting glucose (FPG) and islet function in non-insulin-dependent patients with diabetes mellitus (NIDDM).